GlassScriptPhysician profile
Danielle N Remington
NPI 1780098806
$6,587.28
in general payments reported to CMS, 2019-2025
28 companies · $828 in 2025
The $828 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $207 · 2021: $477 · 2022: $951 · 2023: $1,352 · 2024: $1,525 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.71 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $731.82 | 2024-2025 | |
| Oyster Point Pharma, INC. | $591.34 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $560.34 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $552.12 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Rxsight INC | $501.02 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Lumenis Be INC | $437.80 | 2023 | Optilight |
| Kala Pharmaceuticals, INC. | $415.60 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $403.43 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $330.74 | 2019 | |
| Glaukos Corporation | $299.42 | 2020-2024 | Idose, Istent Inject Trabecular Micro-Bypass System |
| Shire North American Group INC | $264.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $251.79 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $191.44 | 2024-2025 | Syfovre |
| Lkc Technologies, INC. | $143.68 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $136.57 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118.13 | 2022-2025 | |
| Coopervision INC. | $90.00 | 2020 | |
| Dompe US, INC. | $80.24 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $72.27 | 2019-2022 | |
| Sight Sciences, INC. | $68.81 | 2022 | |
| Harrow Eye, LLC | $66.67 | 2025 | Vevye |
| Amgen INC. | $58.45 | 2025 | Tepezza |
| Thea Pharma INC. | $50.88 | 2023-2024 | Iyuzeh |
| Alcon Vision LLC | $47.68 | 2023-2025 | Clareon, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $44.76 | 2019-2023 | Tecnis Iol |
| Ani Pharmaceuticals, INC. | $41.77 | 2024 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $20.19 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $15.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Remington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.